B-MS gets Zeposia approval but delays launch due to coronavirus

26 March 2020
bristol-myers-squibb-big

Bristol-Myers Squibb (NYSE: BMY) has received US approval for Zeposia (ozanimod) for relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

The US pharma major acquired this drug as part of its $74 billion buy of biotech company Celgene last year. It was seen as one of the latter company’s most promising pipeline assets in late-stage development. B-MS’ shares were up 6% at $52.32 by mid-afternoon trading today.

"We are well positioned with our heritage in transformational science to ensure this innovative compound ultimately benefits as many patients as possible"Zeposia is a S1P receptor modulator, joining Novartis’ (NOVN: VX) therapies Gilenya (fingolimod) and Mayzent (siponimod) as approved MS treatments in this class.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology